LGND: Ligand Pharmaceuticals, Inc. - Class B Company Profile & Statistics

About

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.

Info & Links

CEO

Todd C. Davis

Headquarters

555 HERITAGE DRIVE, SUITE 200
JUPITER, FL 33458, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

339

Employees

Ligand Pharmaceuticals, Inc. - Class B Statistics

Valuation Measures

Market Capitalization²

2.32B

Enterprise Value

2.25B

Enterprise Value/EBITDA(ttm)

153.05

Price to Earnings Ratio(ttm)

55.15

Price to Sales(ttm)

14.49

Price to Book(mrq)

2.54

Price to Cash(ytd)

23.37

Profitability

Gross Margin(ttm)

93.28%

Operating Margin(ttm)

25.34%

Profit Margin(ttm)

50.99%

Return on Equity(ttm)

4.95%

Return on Invested Capital(ttm)

5.73%

Return on Assets(ttm)

4.39%

Income Statement

Revenue(ttm)

152.42M

Revenue Per Share(ttm)

8.07

Gross Profit(ttm)

142.54M

EBITDA(ttm)³

14.73M

Net Income Available to Common(ttm)

45.24M

Diluted EPS(ttm)

2.51

Share Statistics

Beta (5Y Monthly)

1.01

52-Week Change

101.10%

S&P 500 52-Week Change

27.63%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

18.90M

Dividend Yield

0.00%

Float⁴

17.78M

% Held by Insiders

5.90%

% Held by Institutions

91.28%

Balance Sheet

Total Cash(mrq)

219.64M

Total Cash Per Share(mrq)

11.62

Total Debt(mrq)

24.00K

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.49%

Quick Ratio(mrq)

11.81%

Book Value Per Share(mrq)

44.84

Cash Flow

Operating Cash Flow Per Share(ytd)

3.72

Free Cash Flow(ytd)

49.65M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

LGND

Ligand Pharmaceuticals, Inc. - Class B

Ligand Pharmaceuticals, Inc. - Class B Profile